Piper Sandler Maintains Overweight on Gossamer Bio, Lowers Price Target to $96

Benzinga · 1d ago
Piper Sandler analyst Yasmeen Rahimi maintains Gossamer Bio (NASDAQ:GOSS) with a Overweight and lowers the price target from $120 to $96.